{"collection_id":"acrin_flt_breast","collection_name":"ACRIN-FLT-Breast","cancer_types":"Breast Cancer","tumor_locations":"Breast","species":"Human","subjects":83,"supporting_data":"Clinical","description":"ACRIN 6688, a 18F -fluorothymidine (FLT) imaging study using positron emission tomography (PET), was\ndesigned to evaluate the relationship between 18F FLT uptake parameters and pathologic complete\nresponse to neoadjuvant therapy of the primary tumor in patients with locally advanced breast\ncancer.\nParticipant Eligibility and Enrollment: Criteria for inclusion were patients with pathologically\nconfirmed breast cancer and determined to be a candidate for primary systemic (neoadjuvant) therapy\nand for whom surgical resection of residual primary tumor following completion of neoadjuvant\ntherapy is planned.\nPlease see the ACRIN-FLT-Breast (https://doi.org/10.7937/K9/TCIA.2017.ol20zmxg) wiki page to learn\nmore about the images and to obtain any supporting metadata for this collection.","patients":83,"studies":363,"series":1480,"instances":688598,"size_TB":0.074,"modalities":["CT","OT","PT"],"licenses":[{"license_short_name":"CC BY 3.0","series":1480,"size_TB":0.074}]}